CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now found that a new type of cell therapy—HIT cells, a cousin to CAR T with enhanced sensitivity—overcomes a major obstacle to treating solid tumors with cell therapy and can completely eliminate kidney, pancreatic, and ovarian cancers in mice. The research appears in the journal Science.
This article was originally published on MedicalXpress.com
